Lifecore and Indomo Sign New Deal to Develop Drug–Device Combination Acne Treatment
Under this new arrangement, the companies will work together to further develop Indomo’s DT-001 candidate, which will be combined with the ClearPen device to allow self-treatment of inflammatory acne lesions.
Fully integrated CDMO, Lifecore Biomedical, and clinical-stage therapeutics company, Indomo, have entered into a new arrangement that will see Lifecore provide Indomo with support to develop an innovative drug–device combination acne treatment. According to a March 4, 2026 press release, the companies will continue development of Indomo’s corticosteroid candidate, DT-001, which will be combined with its investigational intradermal self-injection device, the ClearPen, as a treatment for inflammatory acne lesions (1).
This is the second agreement Lifecore and Indomo have entered into around Indomo’s DT-001 program. In the previous deal, Lifecore provided formulation and process optimization activities for Indomo’s DT-001 program. Under the terms of the latest agreement, Lifecore’s responsibilities will lie in the production and supply of clinical batches of DT-001 to Indomo for planned studies aimed at progressing the program into Phase II clinical trials.
“We are thrilled to continue to grow our relationship with Indomo and support a customer that possesses such high-quality leadership and ambitious plans for innovation. This work with Indomo highlights the success of our continued efforts to expand beyond our traditional focus in ophthalmic therapies, while also enhancing our leadership in rapidly growing autoinjector technologies,” said Paul Josephs, President and Chief Executive Officer of Lifecore, in a company press release (1). “We are excited to get to work on producing engineering and clinical batches for Indomo and supporting the company’s plans to move into Phase 2 studies.”
“As we progress toward Phase II studies, it was critical for Indomo to partner with a CDMO that combines technical excellence with a forward-looking approach to innovation,” added Rick Bente, Chief Executive Officer of Indomo, in the press release (1). “Lifecore’s expanding leadership in injectable therapeutics and their commitment to speed and high-quality execution position them as a key partner in advancing our therapeutic pipeline. We are excited to deepen this collaboration as we move into the next phase of development.”
Intralesional low-dose corticosteroid injections directly into an inflammatory acne lesion is an efficacious method of treatment, providing relief and improvement rapidly compared with other forms of treatment (2). However, if in-office injections are required, it is not easily accessible to all patients and can become costly. Indomo’s drug–device combination has been designed to overcome the challenge of accessibility by making the administration of such a treatment possible in the home setting.
References
Lifecore. Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment. Press Release, March 4, 2026.
Olson, L.B.; Roberts, C.M.; Dhawan, S.S.; et al. Intralesional Triamcinolone for Inflammatory Acne: A Comparative Study of Dose Efficacy and Investigation of a Novel Injection Assistance Device to Enable Self-Administration of Intralesional Therapy. J. Dermatolog. Treat. 2025, 36 (1), 2504656.